BLAINJECTIONINJECTABLEPriority Review
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
5/8 — Partial
Priority Review
KIMMTRAK (tebentafusp) by Immunocore is glycoprotein 100 peptide-human leukocyte antigen-directed antibody interactions [moa]. Approved for uveal melanoma. First approved in 2022.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KIMMTRAK (tebentafusp) is a bispecific gp100 peptide-HLA-directed CD3 T cell engager approved for uveal melanoma, a rare intraocular malignancy. It works by redirecting the patient's own T cells to recognize and kill tumor cells expressing gp100 antigen presented on HLA. This represents a novel immunotherapy approach distinct from checkpoint inhibitors and conventional chemotherapy.
Peak
As a rare-disease product in peak lifecycle phase, the commercial team is likely focused on maximizing penetration in a limited but growing patient population with high unmet need.
Mechanism of Action
Glycoprotein 100 Peptide-Human Leukocyte Antigen-directed Antibody Interactions
Pharmacologic Class:
Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager
Indications (1)
Clinical Trials (9)
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Started Dec 2025
18 enrolled
Metastatic Uveal Melanoma
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
Started Oct 2025
47 enrolled
HLA-A*0201 Positive Cells PresentClear Cell Sarcoma (CCS)
Neoadjuvant Tebentafusp for Uveal Melanoma
Started Sep 2025
19 enrolled
Locally Advanced Unresectable Uveal Melanoma
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Started Aug 2025
44 enrolled
Uveal Melanoma
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
Started Feb 2025
30 enrolled
Metastatic Uveal MelanomaMetastatic Uveal Melanoma in the Liver
Worked on KIMMTRAK at Immunocore? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.